Targeting the C-Met/fzd8 Signaling Axis Eliminates Patient-Derived Cancer Stem-Like Cells in Head and Neck Squamous Carcinomas.

Shuyang Sun,Suling Liu,Sheng Zhong Duan,Lei Zhang,Henghua Zhou,Yongjie Hu,Xianghui Zhou,Chaoji Shi,Rong Zhou,Zhiyuan Zhang
DOI: https://doi.org/10.1158/0008-5472.can-14-0826
IF: 11.2
2014-01-01
Cancer Research
Abstract:Abstract Cancer stem–like cells (CSC) thought to contribute to head and neck squamous carcinomas (HNSCC) may offer attractive therapeutic targets if a tractable approach can be developed. In this study, we report that silencing c-Met is sufficient to suppress sphere formation, tumor initiation, and metastatic properties of HN-CSC. Pharmacologic inhibition of c-Met with the selective inhibitor PF-2341066 preferentially targeted CSC and synergized with conventional chemotherapy to improve efficacy in a mouse xenograft model of HNSCC, impeding tumor growth and reducing metastasis. Mechanistic investigations showed that CSC elimination was due to downregulation of Wnt/β-catenin signaling in HN-CSC and that the Wnt pathway receptor FZD8 was essential for interactions of c-Met and Wnt/β-catenin signaling in HN-CSC. Notably, ectopic expression of FZD8 rescued the impaired phenotype of HN-CSC where c-Met was inhibited. Furthermore, c-Met upregulated FZD8 through the ERK/c-Fos cascade in HN-CSC. Taken together, our results offer a preclinical proof-of-concept for targeting the c-Met/FZD8 signaling axis as a CSC-directed therapy to improve HNSCC treatment. Cancer Res; 74(24); 7546–59. ©2014 AACR.
What problem does this paper attempt to address?